Sensei Biotherapeutics (NASDAQ:SNSE) Given “Buy” Rating at Citigroup

Citigroup restated their buy rating on shares of Sensei Biotherapeutics (NASDAQ:SNSEFree Report) in a report released on Monday, Benzinga reports. The firm currently has a $4.00 target price on the stock.

SNSE has been the topic of several other reports. HC Wainwright restated a buy rating and issued a $4.00 price objective on shares of Sensei Biotherapeutics in a research report on Friday, May 24th. Stephens reissued an overweight rating and issued a $5.00 price target on shares of Sensei Biotherapeutics in a research note on Friday, May 24th.

Read Our Latest Analysis on Sensei Biotherapeutics

Sensei Biotherapeutics Stock Performance

NASDAQ:SNSE opened at $0.73 on Monday. Sensei Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $1.94. The company has a quick ratio of 12.07, a current ratio of 12.07 and a debt-to-equity ratio of 0.01. The firm’s fifty day simple moving average is $1.17 and its 200-day simple moving average is $0.92. The stock has a market cap of $18.26 million, a PE ratio of -0.60 and a beta of 0.06.

Sensei Biotherapeutics (NASDAQ:SNSEGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.03). Analysts expect that Sensei Biotherapeutics will post -1.07 earnings per share for the current fiscal year.

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.

Recommended Stories

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with's FREE daily email newsletter.